The relationship between adipose tissue-derived hormones and gestational diabetes mellitus (GDM)

Endokrynologia Polska

Volumn 65, Issue 2, 2014, Pages 134-142

  Wójcik, Marzena ^a   Chmielewska Kassassir, Małgorzata ^a   Grzywnowicz, Karolina ^a   Woźniak, Lucyna ^a   Cypryk, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adipokines; Adiponectin; Gestational diabetes mellitus (GDM); Leptin; Omentin; RBP 4; Resistin; Vaspin; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPOSE TISSUE DERIVED HORMONE; APELIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG; VASPIN; APLN PROTEIN, HUMAN; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADIPOSE TISSUE; CELL DISRUPTION; HUMAN; INSULIN RESISTANCE; MOLECULAR MECHANICS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PREGNANCY DIABETES MELLITUS; REVIEW; FEMALE; METABOLISM; PREGNANCY;

ADIPOKINES; ADIPONECTIN; DIABETES, GESTATIONAL; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREGNANCY; RESISTIN; RETINOL-BINDING PROTEINS, PLASMA; SERPINS;

EID: 84901445111     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2014.0019     Document Type: Review

References (116)

1. American Diabetes Association: Gestational diabetes mellitus. Diabetes Care 2003; 26: S103-S105.
2. Ryan EA. Diagnosing gestational diabetes. Diabetologia 2011; 54: 480-486.
3. Wójcikowski C, Królikowska B, Konarzewska J et al. The prevalence of gestational diabetes mellitus in Polish population. Ginekol Pol 2002; 73: 811-816.
4. Schmidt MI, Duncan BB, Reichelt AJ et al. Brazilian Gestational Diabetes Study Group. Gestational diabetes mellitus diagnosed with a 2-h 75-g oral glucose tolerance test and adverse pregnancy outcomes. Diabetes Care 2001; 24: 1151-1155. (Pubitemid 33716390)
5. Gilmartin AB, Ural SH, Repke JT. Gestational diabetes mellitus. Rev Obstet Gynecol 2008; 1: 129-134.
6. Petry CJ. Gestational diabetes: risk factors and recent advances in its genetics and treatment. Br J Nutr 2010; 104: 775-787.
7. Chu SY, Callaghan WM, Kim SY et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care 2007; 30: 2070-2076. (Pubitemid 47219422)
8. Blüher M. Clinical relevance of adipokines. Diabetes Metab J 2012; 36: 317-327.
9. Margetic S, Gazzola C, Pegg GG et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26: 1407-1433. (Pubitemid 36007818)
10. Paz-Filho G, Mastronardi C, Wong ML et al. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab 2012; 16 (Suppl. 3): S549-S555.
11. Hegyi K, Fülöp K, Kovács K et al. Leptin-induced signal transduction pathways. Cell Biol Int 2004; 28: 159-169. (Pubitemid 38230226)
12. Shimomura I, Hammer RE, Ikemoto S et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-76.
13. Maffei M, Halaas J, Ravussin E et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-1161.
14. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295. (Pubitemid 26033933)
15. Frederich RC, Löllmann B, Hamann A et al. Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J Clin Invest 1995; 96: 1658-1663.
16. Frederich RC, Hamann A, Anderson S et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1: 1311-1314.
17. Maffei M, Fei H, Lee GH et al. Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci USA 1995; 92: 6957-6960.
18. Hukshorn CJ, van Dielen FM, Buurman WA et al. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 2002; 26: 504-509. (Pubitemid 34407263)
19. Munzberg H. Leptin-signaling pathways and leptin resistance. Forum Nutr 2010; 63: 123-132.
20. Montague CT, Prins JB, Sanders L et al. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997; 46: 342-347. (Pubitemid 27090260)
21. Fried SK, Ricci MR, Russell CD et al. Regulation of leptin production in humans. J Nutr 2000; 130: S3127-S3131.
22. Bates SH, Gardiner JV, Jones RB et al. Acute stimulation of glucose uptake by leptin in l6 muscle cells. Horm Metab Res 2002; 34: 111-115. (Pubitemid 34293266)
23. Minokoshi Y, Kahn BB. Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle. Biochem Soc Trans 2003; 31: 196-201. (Pubitemid 36241427)
24. Ceddia RB, Lopes G, Souza HM et al. Acute effects of leptin on glucose metabolism of in situ rat perfused livers and isolated hepatocytes. Int J Obes Relat Metab Disord 1999; 23: 1207-1212.
25. Zhao AZ, Shinohara MM, Huang D et al. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J Biol Chem 2000; 275: 11348-11354. (Pubitemid 30212785)
26. Huang W, Dedousis N, Bhatt BA et al. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. J Biol Chem 2004; 279: 21695-21700. (Pubitemid 38679354)
27. Ranganathan S, Ciaraldi TP, Henry RR et al. Lack of effect of leptin on glucose transport, lipoprotein lipase, and insulin action in adipose and muscle cells. Endocrinology 1998; 139: 2509-2513. (Pubitemid 28513779)
28. Perez C, Fernandez-Galaz C, Fernandez-Agullo T et al. Leptin impairs insulin signaling in rat adipocytes. Diabetes 2004; 53: 347-353. (Pubitemid 38174549)
29. Marroquí L, Gonzalez A, Ñeco P et al. Role of leptin in the pancreatic â-cell: effects and signaling pathways. J Mol Endocrinol 2012; 49: R9-R17.
30. Kautzky-Willer A, Pacini G, Tura A et al. Increased plasma leptin in gestational diabetes. Diabetologia 2001; 44: 164-172. (Pubitemid 32156200)
31. Chen D, Xia G, Xu P et al. Peripartum serum leptin and soluble leptin receptor levels in women with gestational diabetes. Acta Obstet Gynecol Scand 2010; 89: 1595-1599.
32. Vitoratos N, Salamalekis E, Kassanos D et al. Maternal plasma leptin levels and their relationship to insulin and glucose in gestational-onset diabetes. Gynecol Obstet Invest 2001; 51: 17-21. (Pubitemid 32041403)
33. Soheilykhah S, Mojibian M, Rahimi-Saghand S et al. Maternal serum leptin concentration in gestational diabetes. Taiwan J Obstet Gynecol 2011; 50: 149-153.
34. Sivan E, Whittaker PG, Sinha D et al. Leptin in human pregnancy: the relationship with gestational hormones. Am J Obstet Gynecol 1998; 179: 1128-1132. (Pubitemid 28533758)
35. Masuzaki H, Ogawa Y, Sagawa N et al. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 1997; 3: 1029-1033. (Pubitemid 27391961)
36. Festa A, Shnawa N, Krugluger W et al. Relative hypoleptinaemia in women with mild gestational diabetes mellitus. Diabet Med 1999; 16: 656-662.
37. Simmons D, Breier BH. Fetal overnutrition in polynesian pregnancies and in gestational diabetes may lead to dysregulation of the adipoinsular axis in offspring. Diabetes Care 2002; 25: 1539-1544.
38. Qiu C, Williams MA, Vadachkoria S et al. Increased maternal plasma leptin in early pregnancy and risk of gestational diabetes mellitus. Obstet Gynecol 2004; 103: 519-525. (Pubitemid 40459068)
39. Ashworth CJ, Hoggard N, Thomas L et al. Placental leptin. Rev Reprod 2000; 5: 18-24. (Pubitemid 30050349)
40. Lepercq J, Cauzac M, Lahlou N et al. Overexpression of placental leptin in diabetic pregnancy: a critical role for insulin. Diabetes 1998; 47: 847-850. (Pubitemid 28201820)
41. Lea RG, Howe D, Hannah LT et al. Placental leptin in normal, diabetic and fetal growth-retarded pregnancies. Mol Hum Reprod 2000; 6: 763-769. (Pubitemid 30625867)
42. Lepercq J, Challier JC, Guerre-Millo M et al. Prenatal leptin production: evidence that fetal adipose tissue produces leptin. J Clin Endocrinol Metab 2001; 86: 2409-2413. (Pubitemid 32545684)
43. Lappas M, Yee K, Permezel M et al. Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol 2005; 186: 457-465. (Pubitemid 41404064)
44. Scherer PE, Williams S, Fogliano M et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
45. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998; 12: 335-338. (Pubitemid 28159119)
46. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451. (Pubitemid 40686653)
47. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599. (Pubitemid 30353893)
48. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935. (Pubitemid 32472900)
49. Yamamoto Y, Hirose H, Saito I et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum highdensity lipoprotein cholesterol, independent of body mass index, in the Japanese population. Clin Sci 2002; 103: 137-142.
50. Tschritter O, Fritsche A, Thamer C et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239-243. (Pubitemid 36173174)
51. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-469. (Pubitemid 36577787)
52. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288v1295.
53. Stefan N, Vozarova B, Funahashi T et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-1888. (Pubitemid 34564302)
54. Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator- activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380.
55. Combs TP, Wagner JA, Berger J et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007. (Pubitemid 34164048)
56. Lihn AS, Richelsen B, Pedersen SB et al. Increased expression of TNF-α, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003; 285: E1072-E1080. (Pubitemid 37296329)
57. Cseh K, Baranyl E, Melczer Z. Plasma adiponectin and pregnancy-induced insulin resistance. Diabetes Care 2004; 27: 274-275. (Pubitemid 38196747)
58. Ranheim T, Haugen F, Staff AC et al. Adiponectin is reduced in gestational diabetes mellitus in normal weight women. Acta Obstet Gynecol Scand 2004; 83: 341-347. (Pubitemid 38406813)
59. Catalano PM, Hoegh M, Minium J et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia 2006; 49: 1677-1685. (Pubitemid 43848106)
60. Chen J, Tan B, Karteris E et al. Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines. Diabetologia 2006; 49: 1292-1302.
61. Retnakaran R, Hanley AJ, Raif N et al. Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. Diabetologia 2005; 48: 993-1001. (Pubitemid 40767994)
62. Lain KY, Daftary AR, Ness RB et al. First trimester adipocytokine concentrations and risk of developing gestational diabetes later in pregnancy. Clin Endocrinol (Oxf) 2008; 69: 407-411.
63. Winzer C, Wagner O, Festa A et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004; 27: 1721-1727. (Pubitemid 38857450)
64. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255: 439-447. (Pubitemid 38446357)
65. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312. (Pubitemid 32151228)
66. Yang Y, Xiao M, Mao Y et al. Resistin and insulin resistance in hepatocytes: resistin disturbs glycogen metabolism at the protein level. Biomed Pharmacother 2009; 63: 366-374.
67. Gharibeh MY, Al Tawallbeh GM, Abboud MM et al. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab 2010; 36: 443-449.
68. Tsiotra PC, Tsigos C, Anastasiou E et al. Peripheral mononuclear cell resistin mRNA expression is increased in type 2 diabetic women. Mediators Inflamm 2008; 2008: 892864.
69. Lee JH, Chan JL, Yiannakouris N et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-4856. (Pubitemid 37357535)
70. Pfutzner A, Langenfeld M, Kunt T et al. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 2003; 49: 571-576. (Pubitemid 37493455)
71. Kuzmicki M, Telejko B, Szamatowicz J et al. High resistin and interleukin-6 levels are associated with gestational diabetes mellitus. Gynecol Endocrinol 2009; 25: 258-263.
72. Kralisch S, Stepan H, Kratzsch J et al. Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus. Eur J Endocrinol 2009; 160: 33-38.
73. Megia A, Vendrell J, Gutierrez C et al. Insulin sensitivity and resistin levels in gestational diabetes mellitus and after parturition. Eur J Endocrinol 2008; 158: 173-178. (Pubitemid 351298533)
74. Akdeniz N, Kuyumcuoǧlu U, Kale A et al. Resistin may not associate with gestational diabetes mellitus although insulin resistance. Clin Exp Obstet Gynecol 2011; 38: 236-238.
75. Lobo TF, Torloni MR, Gueuvoghlanian-Silva BY et al. Resistin concentration and gestational diabetes: a systematic review of the literature. J Reprod Immunol 2013; 97: 120-127.
76. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430. (Pubitemid 40139988)
77. Haider DG, Schaller G, Kapiotis S et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914. (Pubitemid 44025046)
78. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/ pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299.
79. Zhang YY, Gottardo L, Thompson R et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006; 14: 2119-2126. (Pubitemid 46121965)
80. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758. (Pubitemid 46154646)
81. Ognjanovic S, Tashima LS, Bryant-Greenwood GD. The effects of pre-B-cell colony-enhancing factor on the human fetal membranes by microarray analysis. Am J Obstet Gynecol 2003; 189: 1187-1195. (Pubitemid 37373920)
82. Krzyzanowska K, Krugluger W, Mittermayer F et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006; 110: 605-609. (Pubitemid 43736123)
83. Lewandowski KC, Stojanovic N, Press M et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007; 50: 1033-1037. (Pubitemid 46559248)
84. Ferreira AF, Rezende JC, Vaikousi E et al. Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin Chem 2011; 57: 609-613.
85. Chan TF, Chen YL, Lee CH et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Invest 2006; 13: 364-367. (Pubitemid 43928662)
86. Boucher J, Masri B, Daviaud D et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764-1771. (Pubitemid 40396885)
87. Castan-Laurell I, Dray C, Attané C et al. Apelin, diabetes, and obesity. Endocrine 2011; 40: 1-9.
88. Li L, Yang G, Li Q et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114: 544-548. (Pubitemid 46087259)
89. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S et al. Apelin levels are increased in morbidly obese subjects with Type 2 Diabetes Mellitus. Obes Surg 2009; 19: 1574-1580.
90. Dray C, Debard C, Jager J et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab 2010; 298: E1161-E1169.
91. Erdem G, Dogru T, Tasci I et al. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116: 289-292. (Pubitemid 351798738)
92. Aslan M, Celik O, Celik N et al. Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine 2012; 41: 424-429.
93. Telejko B, Kuzmicki M, Wawrusiewicz-Kurylonek N et al. Plasma apelin levels and apelin/APJ mRNA expression in patients with gestational diabetes mellitus. Diabetes Res Clin Pract 2010; 87: 176-183.
94. Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contibutes to insulin resistancein obesity and type 2 diabetes. Nature 2005; 436: 356-362. (Pubitemid 41065039)
95. Graham TE, Yang Q, Blüher M et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563. (Pubitemid 43882351)
96. Lewis JG, Shand BI, Frampton CM et al. Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: a three year longitudinal study. Clin Biochem 2008; 41:1034-1038.
97. Ueland T, Dalsoren T, Voldner N et al. Retinol-binding protein-4 is not strongly associated with insulin sensitivity in normal pregnancies. Eur J Endocrinol 2008; 159: 49-54. (Pubitemid 351969130)
98. Inoue S, Takamoto N, Akahori Y et al. Elevated level of serum retinol-binding protein 4 in pregnancy-induced hypertension. J Obstet Gynaecol Res 2009; 35: 293-300.
99. Lewandowski KC, Stojanovic N, Bienkiewicz M et al. Elevated concentrations of retinol-binding protein-4 (RBP-4) in gestational diabetes mellitus: negative correlation with soluble vascular cell adhesion molecule-1 (sVCAM-1). Gynecol Endocrinol 2008; 24: 300-305. (Pubitemid 351918003)
100. Krzyzanowska K, Zemany L, Krugluger W et al. Serum concentrations of retinol-binding protein 4 in women with and without gestational diabetes. Diabetologia 2008; 51: 1115-1122.
101. Khovidhunkit W, Pruksakorn P, Plengpanich W et al. Retinol-binding protein 4 is not associated with insulin resistance in pregnancy. Metabolism 2012; 61: 65-69.
102. Hida K, Wada J, Eguchi J et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005; 102: 10610-10615. (Pubitemid 41061602)
103. Klöting N, Berndt J, Kralisch S et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-436. (Pubitemid 41697566)
104. Caminos JE, Bravo SB, Garcés MF et al. Vaspin and amylin are expressed in human and rat placenta and regulated by nutritional status. Histol Histopathol 2009; 24: 979-990.
105. Giomisi A, Kourtis A, Toulis KA et al. Serum vaspin levels in normal pregnancy in comparison with non-pregnant women. Eur J Endocrinol 2011; 164: 579-583.
106. Stepan H, Kralisch S, Klostermann K et al. Preliminary report: circulating levels of the adipokine vaspin in gestational diabetes mellitus and preeclampsia. Metabolism 2010; 59: 1054-1056.
107. Gkiomisi A, Makedou KG, Anastasilakis AD et al. Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. Cytokine 2013; 61: 127-132.
108. Schaffler A, Neumeier M, Herfarth H et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005; 1732: 96-102.
109. Xiang K, Wang Y, Zheng T et al. Genome-wide search for type 2 diabetes/ impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes 2004; 53: 228-234. (Pubitemid 38044720)
110. Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-1261. (Pubitemid 43847911)
111. de Souza Batista CM, Yang RZ, Lee MJ et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661.
112. Pan HY, Guo L, Li Q: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010; 88: 29-33.
113. Yan P, Liu D, Long M et al. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 257-263.
114. Tan BK, Adya R, Farhatullah S et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-808.
115. Barker G, Lim R, Georgiou HM et al. Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity. PLoS One 2012; 7: e42943.
116. Zieleniak A, Cypryk K, Wozniak LA et al. Adenosine receptors expression is elevated in leukocytes of gestational diabetes mellitus (GDM) subjects - a preliminary study. Endokrynol Pol 2012; 63: 110-114.